Ventus Therapeutics Reports Results from the P-I Study of VENT-02 in Healthy Volunteers
Shots:
- The P-I study assesses the safety, tolerability and PK/PD of VENT-02 (oral), a brain-penetrant NLRP3 inhibitor, in a range of single and multiple ascending doses among healthy volunteers
- The study showed that VENT-02 was well-tolerability without any DLTs or SAEs with only mild or moderate TRAEs, achieved 100% IL-1β inhibition in ex vivo whole blood challenge assay & significant drug levels in CSF for 24hrs. plus reduced hsCRP as well as indicated potential of QD dosing
- Furthermore, the company anticipates the commencement of the P-Ib study for Parkinson’s disease in H2’24 & the P-II study for treatment-refractory epilepsy in 2025
Ref: Ventus Therapeutics | Image: Ventus Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
